In a study by Tye et al. conducted in 2022, canagliflozin was commenced for the treatment of T2DM based on a multivariable risk prediction model, as well as a model based on HBA1c or urine albumin to creatinine ratio (UACR) alone [27]. This evidence concerns the gene ALB and type 2 diabetes mellitus.